Orforglipron pill achieved 12% weight loss

Eli Lilly's obesity pill, orforglipron, achieved nearly 12% weight loss in a late-stage trial. The daily pill helped patients lose approximately 27 pounds over 72 weeks, offering a needle-free alternative to existing weight loss treatments. This development could expand access to obesity care, potentially reaching millions who could benefit from such medications.